Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>Events>This Event
  Events - November 2014

Advances in Cell Based Assays

11 Nov 2014 - 12 Nov 2014 - London, UK

Bookmark and Share

SMi Group invites you to attend the market leading cell based event, Advances in Cell Based Assays, taking place on 11th & 12th November in Central London.

We have worked closely with an array of industry KOLs and scientific leaders to host a packed conference agenda for the 7th annual conference this autumn

Expand your scientific horizons as we ask the questions: 

  • How have recent advances in high throughput sample expression techniques opened up new possibilities for primary HTS within the biologics industry? 
  • What are the current challenges of bioassay method development and how can we validate these with reference to cell based assays and regulatory guidelines in drug development? 
  • What is the next generation of target identification and screening technologies? 
  • How easy is it to use adult stem cells in therapeutic applications, in vitro and in vivo paradigm?
  • How can we exploit gene editing in human cell lines to provide novel, isogenic assays? 
  • How are new technologies impacting the industry? 
  • 3D cell culture, how can this be used in oncology research? 
  • What is the next generation of cell based assays?

Key Speakers Include:

  • Steve Ludbrook, Group Leader, Biological Sciences UK, RD Platform Technology & Science, GSK
  • Beverley Isherwood, Team Leader High Content Biology, Innovative Medicines, AstraZeneca R&D
  • Dr Lesley Jenkinson, Scientist 1, Medimmune
  • Dr Farnaz Fallah-Arani, Group Leader, Pharmacology, UCB
  • Neil Carragher, PhD, Principal Investigator Drug Discovery, Edinburgh Cancer Research UK Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh
  • Niclas Nilsson, Head of Section, Lead Discovery, LEO Pharma
  • Dr Christa Burger, Principal Scientist, Cellular Pharmacology, Merck Serono
  • Dr Marianne Uteng, PhD, Head of Cellular Models & HCB Laboratory, Discovery and Investigative Safety (DIS), Novartis
  • Anker Jon Hansen, Principal Scientist, Novo Nordisk
  • Daniel Nolan, Director of Research, Angiocrine Bioscience

For further details and to download a copy of the PDF,  visit 

Alternatively contact Fateja Begum on +44 (0)20 7827 6184 or email

Further information
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos